Compound ID | 1533
Class: Nucleoside analogue
| Agent Type: | Natural product; Direct acting; |
| Spectrum of activity: | Gram-positive |
| Mechanism of action: | Cell wall synthesis inhibitor. Inhibits transfer of the peptidoglycan precursor moiety (MurNAc-pentapeptide) to the membrane lipid carrier, undecaprenyl phosphate; MraY inhibitor |
| Target Pathogen: | Active against Staphylococcus aureus |
| Description: | Natural product from Streptosporangium sp.; muraminomicin derivative |
| Institute where first reported: | Medicinal Chemistry Research Laboratories, Daiichi Sankyo Co., Ltd., Tokyo, Japan |
| Year first mentioned: | 2019 |
| Development status: | Experimental |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/145720731 |
| Guide to Pharmacology: | muraminomicin F |
| Citation: | https://www.nature.com/articles/s41429-019-0235-3 |